CN102495215A - 一种定量检测肿瘤坏死因子α的试剂盒 - Google Patents
一种定量检测肿瘤坏死因子α的试剂盒 Download PDFInfo
- Publication number
- CN102495215A CN102495215A CN2011103997282A CN201110399728A CN102495215A CN 102495215 A CN102495215 A CN 102495215A CN 2011103997282 A CN2011103997282 A CN 2011103997282A CN 201110399728 A CN201110399728 A CN 201110399728A CN 102495215 A CN102495215 A CN 102495215A
- Authority
- CN
- China
- Prior art keywords
- tnf
- kit
- fully
- container
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 40
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title claims abstract 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 31
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 238000007885 magnetic separation Methods 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 239000011324 bead Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 24
- 239000008213 purified water Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 10
- 239000012744 reinforcing agent Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 150000001718 carbodiimides Chemical class 0.000 claims description 6
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000006148 magnetic separator Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- -1 TNF-α compound Chemical class 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 9
- 239000006249 magnetic particle Substances 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 34
- 208000006673 asthma Diseases 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
浓度 | 加入校准品稀释液体积 | 加入X体积 |
A | V-A*V/X | A*V/X |
B | V-B*V/X | B*V/X |
C | V-C*V/X | C*V/X |
D | V-D*V/X | D*V/X |
E | V-E*V/X | E*V/X |
F | V-F*V/X | F*V/X |
组别 | 对照组(ng/ml) | 急性发作组(ng/ml) | 缓解组(ng/ml) |
TNF-α含量 | 0.178±0.011 | 0.872±0.167 | 0.235±0.049 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110399728.2A CN102495215B (zh) | 2011-12-06 | 2011-12-06 | 一种定量检测肿瘤坏死因子α的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110399728.2A CN102495215B (zh) | 2011-12-06 | 2011-12-06 | 一种定量检测肿瘤坏死因子α的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102495215A true CN102495215A (zh) | 2012-06-13 |
CN102495215B CN102495215B (zh) | 2014-01-22 |
Family
ID=46187056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110399728.2A Expired - Fee Related CN102495215B (zh) | 2011-12-06 | 2011-12-06 | 一种定量检测肿瘤坏死因子α的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102495215B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998457A (zh) * | 2012-07-12 | 2013-03-27 | 电子科技大学 | 草鱼肿瘤坏死因子alpha的竞争抑制酶联免疫检测方法 |
CN103823064A (zh) * | 2014-03-03 | 2014-05-28 | 中华人民共和国张家港出入境检验检疫局 | 一种呕吐毒素定量检测试剂盒及其使用方法 |
CN104198721A (zh) * | 2014-07-28 | 2014-12-10 | 北京润诺思医疗科技有限公司 | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 |
CN105467137A (zh) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | 游离人绒毛膜性腺激素β亚单位测试试剂盒及其测试方法 |
CN106918633A (zh) * | 2017-04-24 | 2017-07-04 | 中国科学院苏州生物医学工程技术研究所 | 基于适体和金磁纳米颗粒的细胞因子TNF‑α的检测方法 |
CN110672857A (zh) * | 2019-10-10 | 2020-01-10 | 四川大学华西第二医院 | 一种TNF-α的高敏Elisa检测试剂盒及其使用方法与应用 |
CN113552368A (zh) * | 2021-07-21 | 2021-10-26 | 苏州立禾生物医学工程有限公司 | 肿瘤坏死因子α检测试剂盒及其检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101377490A (zh) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | 用于检测疾病相关标志物的磁微粒分离化学发光免疫分析测定试剂盒及其制备方法 |
WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
CN102016552A (zh) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | 用于分子的高灵敏性检测的方法和组合物 |
-
2011
- 2011-12-06 CN CN201110399728.2A patent/CN102495215B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101377490A (zh) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | 用于检测疾病相关标志物的磁微粒分离化学发光免疫分析测定试剂盒及其制备方法 |
CN102016552A (zh) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | 用于分子的高灵敏性检测的方法和组合物 |
WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998457A (zh) * | 2012-07-12 | 2013-03-27 | 电子科技大学 | 草鱼肿瘤坏死因子alpha的竞争抑制酶联免疫检测方法 |
CN102998457B (zh) * | 2012-07-12 | 2015-08-26 | 电子科技大学 | 草鱼肿瘤坏死因子alpha的竞争抑制酶联免疫检测方法 |
CN103823064A (zh) * | 2014-03-03 | 2014-05-28 | 中华人民共和国张家港出入境检验检疫局 | 一种呕吐毒素定量检测试剂盒及其使用方法 |
CN103823064B (zh) * | 2014-03-03 | 2016-05-25 | 中华人民共和国张家港出入境检验检疫局 | 一种呕吐毒素定量检测试剂盒及其使用方法 |
CN104198721A (zh) * | 2014-07-28 | 2014-12-10 | 北京润诺思医疗科技有限公司 | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 |
CN105467137A (zh) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | 游离人绒毛膜性腺激素β亚单位测试试剂盒及其测试方法 |
CN106918633A (zh) * | 2017-04-24 | 2017-07-04 | 中国科学院苏州生物医学工程技术研究所 | 基于适体和金磁纳米颗粒的细胞因子TNF‑α的检测方法 |
CN106918633B (zh) * | 2017-04-24 | 2019-06-25 | 中国科学院苏州生物医学工程技术研究所 | 基于适体和金磁纳米颗粒的细胞因子TNF-α的检测方法 |
CN110672857A (zh) * | 2019-10-10 | 2020-01-10 | 四川大学华西第二医院 | 一种TNF-α的高敏Elisa检测试剂盒及其使用方法与应用 |
CN113552368A (zh) * | 2021-07-21 | 2021-10-26 | 苏州立禾生物医学工程有限公司 | 肿瘤坏死因子α检测试剂盒及其检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102495215B (zh) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102495215B (zh) | 一种定量检测肿瘤坏死因子α的试剂盒 | |
CN102662059B (zh) | 一种用于测定幽门螺杆菌抗体的胶乳增强免疫比浊试剂盒及其制备方法和应用 | |
CN104316683B (zh) | 针对全血的卵巢癌细胞检测试剂盒 | |
CN103173420B (zh) | 可分泌抗心肌肌钙蛋白i单抗的杂交瘤细胞及应用 | |
CN101581726B (zh) | 新一代布鲁氏菌病抗体竞争酶联免疫吸附试验检测试剂盒 | |
CN103364558A (zh) | 一种人肿瘤标志物癌胚抗原(cea)的磁微粒化学发光免疫分析试剂盒及其检测方法 | |
CN104568923A (zh) | 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒 | |
CN101520458A (zh) | 金标免疫分析检测hla-g及其抗体的简易方法 | |
CN103323592B (zh) | 高通量毒品毒物快速检测芯片及*** | |
CN101592661B (zh) | 布鲁氏菌病抗体竞争酶联免疫吸附试验检测试剂盒 | |
CN102520176B (zh) | 一种定量检测白介素8的试剂盒 | |
CN103076455A (zh) | 快速定量检测血清淀粉样蛋白a试剂盒及其制备和应用 | |
CN105842464B (zh) | 基于上转换发光技术的联合定量检测uNGAL和uCr的装置及其制备方法 | |
CN104142401A (zh) | ***相关抗原检测试剂盒 | |
CN104965089A (zh) | 新型微柱凝胶法血小板抗体检测试剂盒及其制备方法 | |
CN101320041B (zh) | 一种快速定量检测c-反应蛋白的胶体金法及其应用 | |
CN101592660A (zh) | 布鲁氏菌病间接酶联免疫吸附试验奶液抗体检测试剂盒 | |
CN107271692B (zh) | 一种标记特异性高亲和力重组抗体的荧光微球及其应用 | |
CN105424941A (zh) | Akr1b10蛋白和用于肝硬化诊断的试剂盒 | |
CN102331502B (zh) | 人s100蛋白(s-100)定量测定试剂盒 | |
CN104730231B (zh) | 一种用于荧光免疫定量检测的样本缓冲液及其应用 | |
JP2018173334A (ja) | 免疫学的測定方法及びそれに用いる試薬キット | |
JP7081861B1 (ja) | LIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット、およびその製造方法 | |
De Gast et al. | The human immune response to α‐haemocyanin of Helix pomatia | |
CN115166238A (zh) | 羊布鲁氏菌病初筛和确诊一体化抗体检测试纸条 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI SHOUWEI Effective date: 20150227 Owner name: WUHAN ANNA NANO BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: REN QINGYUAN Effective date: 20150227 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 273400 LINYI, SHANDONG PROVINCE TO: 430000 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150227 Address after: 430000 East Lake Hubei New Technology Development Zone, Wuhan high tech Avenue, No. 666 Wuhan national biological industry base project B, C, D District R & D building B1 Patentee after: An Wuhan nano Biological Technology Co., Ltd. Address before: 273400 Department of clinical laboratory, Feixian County people's Hospital, 71 health Road, Shandong, Linyi, Feixian County Patentee before: Ren Qingyuan Patentee before: Li Shouwei |
|
TR01 | Transfer of patent right |
Effective date of registration: 20181221 Address after: 430000 East Lake New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Kersi Biotechnology Co., Ltd. Address before: 430000 Development Building B1 of Wuhan National Biological Industrial Base Project B, C and D, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee before: An Wuhan nano Biological Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20201206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |